Cancer immunology is a growing field of research that aims to identify biomarkers in cancer immunodiagnosis and to discover innovative cancer immunotherapies. The immune system can recognize the antigenic changes in cancer cells and further develop antibodies against these cellular antigens that have been generally called tumor-associated antigens (TAAs). These cancer-associated autoantibodies (TAAbs) might be considered as “reporters” from the immune system to identify the antigenic changes in cellular proteins involved in the transformation process. There has been a growing interest in using serum autoantibodies against TAAs as biomarkers in cancer immunodiagnosis, as well as immunotherapy.
In the last few years, major developments have been made in the field of research on TAAs and TAAbs. The diagnostic value, clinical utility, and pathogenic significance of TAAs or TAAbs are the focus of ongoing research. The current Research Topic focuses on TAAs, especially on discovering novel TAAs by using high throughput techniques, such as sequencing, protein array, mass spectrum, as well as their corresponding autoantibodies regarding clinical utility as biomarkers.
In this Research Topic, we welcome original research articles and reviews that focus on, but are not limited to, the following themes:
- Discovering novel TAAs by using high-throughput techniques, such as protein array, immunomics approach, and mass spectrometry.
- Identification and characterization of TAAs and their TAAbs that are associated with cancer detection and immunodiagnosis.
- Identification and characterization of TAAs as potential candidates in cancer vaccine development or as potential targets in cancer immunotherapy.
- Basic studies of TAAs involved in tumorigenesis.
- Unique properties of TAAbs and their relevance to disease.
- Diagnostic, clinical, and prognostic significance of TAAbs.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic
Cancer immunology is a growing field of research that aims to identify biomarkers in cancer immunodiagnosis and to discover innovative cancer immunotherapies. The immune system can recognize the antigenic changes in cancer cells and further develop antibodies against these cellular antigens that have been generally called tumor-associated antigens (TAAs). These cancer-associated autoantibodies (TAAbs) might be considered as “reporters” from the immune system to identify the antigenic changes in cellular proteins involved in the transformation process. There has been a growing interest in using serum autoantibodies against TAAs as biomarkers in cancer immunodiagnosis, as well as immunotherapy.
In the last few years, major developments have been made in the field of research on TAAs and TAAbs. The diagnostic value, clinical utility, and pathogenic significance of TAAs or TAAbs are the focus of ongoing research. The current Research Topic focuses on TAAs, especially on discovering novel TAAs by using high throughput techniques, such as sequencing, protein array, mass spectrum, as well as their corresponding autoantibodies regarding clinical utility as biomarkers.
In this Research Topic, we welcome original research articles and reviews that focus on, but are not limited to, the following themes:
- Discovering novel TAAs by using high-throughput techniques, such as protein array, immunomics approach, and mass spectrometry.
- Identification and characterization of TAAs and their TAAbs that are associated with cancer detection and immunodiagnosis.
- Identification and characterization of TAAs as potential candidates in cancer vaccine development or as potential targets in cancer immunotherapy.
- Basic studies of TAAs involved in tumorigenesis.
- Unique properties of TAAbs and their relevance to disease.
- Diagnostic, clinical, and prognostic significance of TAAbs.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic
